Exchange: NASDAQ·Updated 07:30 PM EST
BLRX logo

BLRX BioLineRx, Ltd.

$0.99
$0.0961
(9.07%)
Today
Closed $0.9639
$0.0261
(2.71%)
After Hours
EarningsNov 23
Mkt Cap$4.8M
Vol38,775.00

About BLRX

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
47

Neutral Sentiment

How do you feel about BLRX?

DiaJay
$BLRX Just a monthly PSA here, this company is a scam stock. There is no future to invest in. This is the hallmark of “Wolves of Wall Street.” There are countless stories of people betrayed and I for one will never let it go.
5
cubfan22
$BLRX FDA approval of Aphexda set this company and its investors on the road to ruin. I still don't understand how Phil remains as CEO following the BioLine USA debacle that cost the company tens of millions of dollars. Any normal company would have replaced their CEO following that.
1
BlakeTaylor12
$BLRX been waiting for a year for them to get enough funding for glix p1. finally happened... time to reload my position and will sell on glix data next year. very happy with this deal. aphexda wasnt making them any money anyways.
1
ilikemoney247
$BLRX remember when stealin your thunder pumped this sooo hard and then instantly disappeared off the face of the earth??
1
tankwfwf
$BLRX rember phil made an offering when the stock was 1.20 at .80 to one of his buddies and thats when he was leading investors to think aphexa was a game changer.He is a worthless liar and thief. The spanking is coming, best to get out.
1
TwongStocks
$BLRX Here is the SEC filing https://www.sec.gov/Archives/edgar/data/1498403/000117891326005266/zk2636437.htm One thing to note regarding the Kreos/Blackrock loan. They are using $3m to prepay a portion of the loan. That will leave an outstanding balance of about $2m on their loan. With $3m going towards loan prepayment, that will leave them with about $2.6m in proceeds for operations. Which I assume will primarily be used for GLIX1 development.
focafoca99
$BLRX executed a $5.6M royalty monetization transaction, selling 80% of future APHEXDA royalties to a Soleus Capital affiliate.
TwongStocks
$BLRX BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital https://www.prnewswire.com/news-releases/biolinerx-enters-into-5-6-million-royalty-monetization-transaction-with-soleus-capital-302943737.html • Soleus will acquire BLRX's 14.4% royalty interest in future net sales of APHEXDA under the Company's existing license agreement with Ayrmid Pharma. • BLRX retained its rights to receive potential commercial milestone payments under the Ayrmid agreement. However, they will no longer report Aphexda royalties from Ayrmid in future earnings. • The $5.6M will support clinical development of GLIX1 & partial partial loan repayment to BlackRock. • In connection with the partial loan repayment, the Company's minimum cash balance requirement under the loan agreement (currently $4 million) will be eliminated. They are continuing their pivot away from Aphexda and towards GLIX1.
Rayvio_News_Filter
$BLRX 💰 BioLineRx Ltd. entered a $5.6 million royalty monetization transaction with Soleus Capital Management, L.P., selling rights to certain future APHEXDA royalties to provide non-dilutive capital for GLIX1 clinical development. Market-relevant event
BlakeTaylor12
$BLRX new pdac vaccine with impressive early results. i think our pdac program is dead. how will they fund the glix program?

Advertisement|Remove ads.